Search

Your search keyword '"Milisen K"' showing total 22 results
Start Over Author "Milisen K" Publisher elsevier ltd
22 results on '"Milisen K"'

1. Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium

Author

Kenis, C., Decoster, L., Flamaing, J., Debruyne, P.R., De Groof, I., Focan, C., Cornélis, F., Verschaeve, V., Bachmann, C., Bron, D., Luce, S., Debugne, G., Van den Bulck, H., Goeminne, J.-C., Schrijvers, D., Geboers, K., Petit, B., Langenaeken, C., Van Rijswijk, R., Specenier, P., Jerusalem, G., Praet, J.-P., Vandenborre, K., Lobelle, J.-P., Lycke, M., Milisen, K., and Wildiers, H.

Published
2018
Full Text
View/download PDF

3. SIOG2023-5-P-386 - Palliative care at the end-of-life in older patients with cancer and associated age-related factors

Author

Depoorter, V., Vanschoenbeek, K., Decoster, L., Silversmit, G., Debruyne, P., De Groof, I., Bron, D., Cornélis, F., Luce, S., Focan, C., Verschaeve, V., Debugne, G., Langenaeken, C., Van Den Bulck, H., Goeminne, J.C., Teurfs, W., Jerusalem, G., Schrijvers, D., Petit, B., Rasschaert, M., Praet, J.P., Vandenborre, K., De Schutter, H., Milisen, K., Flamaing, J., Kenis, C., Verdoodt, F., and Wildiers, H.

Published
2023
Full Text
View/download PDF

4. SIOG2023-5-P-342 - End-of-life healthcare utilization in older patients with cancer: a large Belgian data linkage study

Author

Depoorter, V., Vanschoenbeek, K., Decoster, L., Silversmit, G., Debruyne, P., De Groof, I., Bron, D., Cornélis, F., Luce, S., Focan, C., Verschaeve, V., Debugne, G., Langenaeken, C., Van Den Bulck, H., Goeminne, J.C., Teurfs, W., Jerusalem, G., Schrijvers, D., Petit, B., Rasschaert, M., Praet, J.P., Vandenborre, K., De Schutter, H., Milisen, K., Flamaing, J., Kenis, C., Verdoodt, F., and Wildiers, H.

Published
2023
Full Text
View/download PDF

7. SIOG2022-0116 - Hospitalizations, emergency department visits and home care in older patients after cancer diagnosis: results from a large data linkage study with 3 year follow-up

Author

Depoorter, V., Vanschoenbeek, K., Decoster, L., De Schutter, H., Debruyne, P.R., De Groof, I., Bron, D., Cornélis, F., Luce, S., Focan, C., Verschaeve, V., Debugne, G., Langenaeken, C., Van Den Bulck, H., Goeminne, J.C., Teurfs, W., Jerusalem, G., Schrijvers, D., Petit, B., Rasschaert, M., Praet, J.P., Vandenborre, K., Milisen, K., Flamaing, J., Kenis, C., Verdoodt, F., and Wildiers, H.

Published
2022
Full Text
View/download PDF

9. SIOG2021-0161 - Geriatric screening and assessment among older patients with cancer: evaluation of long-term outcomes in a multicentric cohort of > 7, 000 patients

Author

Depoorter, V., Vanschoenbeek, K., Decoster, L., De Schutter, H., Debruyne, P.R., De Groof, I., Bron, D., Cornélis, F., Luce, S., Focan, C., Verschaeve, V., Debugne, G., Langenaeken, C., Van Den Bulck, H., Goeminne, J.C., Teurfs, W., Jerusalem, G., Schrijvers, D., Petit, B., Geboers, K., Forceville, K., Praet, J.P., Vandenborre, K., Milisen, K., Flamaing, J., Kenis, C., Verdoodt, F., and Wildiers, H.

Published
2021
Full Text
View/download PDF

22. Long-term health-care utilisation in older patients with cancer and the association with the Geriatric 8 screening tool: a retrospective analysis using linked clinical and population-based data in Belgium.

Author

Depoorter V, Vanschoenbeek K, Decoster L, Silversmit G, Debruyne PR, De Groof I, Bron D, Cornélis F, Luce S, Focan C, Verschaeve V, Debugne G, Langenaeken C, Van Den Bulck H, Goeminne JC, Teurfs W, Jerusalem G, Schrijvers D, Petit B, Rasschaert M, Praet JP, Vandenborre K, Milisen K, Flamaing J, Kenis C, Verdoodt F, and Wildiers H

Subjects
Humans, Aged, Retrospective Studies, Belgium epidemiology, Patient Acceptance of Health Care, Early Detection of Cancer, Neoplasms diagnosis, Neoplasms epidemiology, Neoplasms therapy
Abstract

Background: Little evidence is available on the long-term health-care utilisation of older patients with cancer and whether this is associated with geriatric screening results. We aimed to evaluate long-term health-care utilisation among older patients after cancer diagnosis and the association with baseline Geriatric 8 (G8) screening results., Methods: For this retrospective analysis, we included data from three cohort studies for patients (aged ≥70 years) with a new cancer diagnosis who underwent G8 screening between Oct 19, 2009 and Feb 27, 2015, and who survived more than 3 months after G8 screening. The clinical data were linked to cancer registry and health-care reimbursement data for long-term follow-up. The occurrence of outcomes (inpatient hospital admissions, emergency department visits, use of intensive care, contacts with general practitioner [GP], contacts with a specialist, use of home care, and nursing home admissions) was assessed in the 3 years after G8 screening. We assessed the association between outcomes and baseline G8 score (normal score [>14] or abnormal [≤14]) using adjusted rate ratios (aRRs) calculated from Poisson regression and using cumulative incidence calculated as a time-to-event analysis with the Kaplan-Meier method., Findings: 7556 patients had a new cancer diagnosis, of whom 6391 patients (median age 77 years [IQR 74-82]) met inclusion criteria and were included. 4110 (64·3%) of 6391 patients had an abnormal baseline G8 score (≤14 of 17 points). In the first 3 months after G8 screening, health-care utilisation peaked and then decreased over time, with the exception of GP contacts and home care days, which remained high throughout the 3-year follow-up period. Compared with patients with a normal baseline G8 score, patients with an abnormal baseline G8 score had more hospital admissions (aRR 1·20 [95% CI 1·15-1·25]; p<0·0001), hospital days (1·66 [1·64-1·68]; p<0·0001), emergency department visits (1·42 [1·34-1·52]; p<0·0001), intensive care days (1·49 [1·39-1·60]; p<0·0001), general practitioner contacts (1·19 [1·17-1·20]; p<0·0001), home care days (1·59 [1·58-1·60]; p<0·0001), and nursing home admissions (16·7% vs 3·1%; p<0·0001) in the 3-year follow-up period. At 3 years, of the 2281 patients with a normal baseline G8 score, 1421 (62·3%) continued to live at home independently and 503 (22·0%) had died. Of the 4110 patients with an abnormal baseline G8 score, 1057 (25·7%) continued to live at home independently and 2191 (53·3%) had died., Interpretation: An abnormal G8 score at cancer diagnosis was associated with increased health-care utilisation in the subsequent 3 years among patients who survived longer than 3 months., Funding: Stand up to Cancer, the Flemish Cancer Society., Competing Interests: Declaration of interests LD reports a research grant (via their institution) from Boehringer Ingelheim; consulting fees from Roche; lecture fees from Roche, Bristol Myers Squibb, MSD, Servier, and Sanofi; travel expenses from Roche, AstraZeneca, and MSD; and advisory board fees from MSD, Bristol Myers Squibb, and AstraZeneca. PRD reports a research grant (via their institution) from Pfizer; consulting fees from Bristol Myers Squibb, Merck/Pfizer, and Ipsen; lecture fees from Bayer; travel expenses from Janssen; and owns stock in Alkermes and Biocartis Group NV. GJ reports research grants (via their institution) from Novartis, Roche, and Pfizer; and reports consulting fees, lecture fees, travel expenses, or advisory board fees from Novartis, Amgen, Roche, Pfizer, Bristol Myers Squibb, Eli Lilly, AstraZeneca, Daiichi Sankyo, AbbVie, Seagen, Medimmune, and Merck. DB reports consulting fees from Incyte and travel expenses from the European Hematology Association, I-Well, Abbvie, and Janssen. JF received advisory board fees or lecture fees (via their institution) from Pfizer, GlaxoSmithKline, Merck, and Janssen. HW received research grants (via their institution) from Roche, Novartis, and Gilead; and received consulting fees, lecture fees, or travel expenses from AbbVie, Daiichi, Gilead, Eli Lilly, Pfizer, AstraZeneca, EISAI, Immutep Pty, MSD, AstraZeneca Ireland, and Relay Therapeutics. All other authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results